Oncology – Gynecologic

RCT: No benefit from immune checkpoint inhibitors in newly diagnosed stage III or IV ovarian cancer

25 Apr, 2021 | 20:57h | UTC

Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer: Placebo-Controlled Randomized Phase III Trial (IMagyn050/GOG 3015/ENGOT-OV39) – Journal of Clinical Oncology

Editorial: Immune Checkpoint Inhibitors in Ovarian Cancer: Can We Bridge the Gap Between IMagynation and Reality?

 

---

RCT: Treatments for vulnerable older adult women with ovarian cancer compared

23 Apr, 2021 | 08:15h | UTC

Efficacy and Safety of First-line Single-Agent Carboplatin vs Carboplatin Plus Paclitaxel for Vulnerable Older Adult Women With Ovarian Cancer: A Randomized Clinical Trial – JAMA Oncology (free for a limited period)

Editorial: Vulnerable Older Adults With Ovarian Cancer—Time to Stop Undertreating (free for a limited period)

 

---

RCT: Secondary cytoreduction followed by chemotherapy vs. chemotherapy alone in platinum-sensitive relapsed ovarian cancer

10 Mar, 2021 | 08:18h | UTC

Secondary cytoreduction followed by chemotherapy versus chemotherapy alone in platinum-sensitive relapsed ovarian cancer (SOC-1): a multicentre, open-label, randomised, phase 3 trial – The Lancet Oncology (link to abstract – $ for full-text)

 

Commentary on Twitter

NEW online: SOC-1 trial—Secondary #cytoreduction followed by #chemotherapy versus chemotherapy alone in platinum-sensitive relapsed #ovariancancer #surgery #gyncsm https://t.co/cFq41Ck9EW pic.twitter.com/5gFsIGLBDA

— The Lancet Oncology (@TheLancetOncol) March 9, 2021

 

---

[Abstract Only] Nationwide cohort study in Sweden shows HPV vaccination linked to reduced risk of invasive cervical cancer

1 Oct, 2020 | 08:56h | UTC

HPV Vaccination and the Risk of Invasive Cervical Cancer – New England Journal of Medicine

News Release: HPV vaccine effective against cervical cancer – Karolinska Institutet

 

---